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BACKGROUND: Thyroid cancers are difficult to treat due to their limited responsiveness to chemo- and radiotherapy. There is thus a
great interest in and a need for alternative therapeutic approaches.
RESULTS: We studied the cytotoxic activity of anti-thyroperoxidase autoantibodies (anti-TPO aAbs, expressed in baculovirus/insect cell
(B4) and CHO cells (B40) or purified from patients’ sera) against a papillary thyroid cancer (NPA) cell line. Anti-TPO aAbs from
patients’ sera led to a partial destruction of NPA cell line by complement-dependent cytotoxicity (CDC) and antibody-dependent
cell-mediated cytotoxicity (ADCC) and exhibited an anti-proliferative activity. Comparison of the cytotoxic activity of anti-TPO aAbs
shows that B40 induced an anti-proliferative effect and a better ADCC than B4, but a lower one than anti-TPO aAbs from patients’
sera. Antibody-dependent cell-mediated cytotoxicity was increased when human peripheral blood mononuclear cells were used as
effector cells, suggesting that FcgRs, CD64, CD32 and CD16 are involved. Indeed, anti-TPO aAbs from patients’ sera, but not B4 and
B40, exhibited CDC activity.
CONCLUSIONS: These data indicate that anti-TPO aAbs display moderate ADCC and anti-proliferative activities on NPA cells; IgG
glycosylation appears to be important for cytotoxic activity and ADCC efficiency depends on FcgR-bearing cells. Finally, recombinant
human anti-TPO aAbs cannot yet be considered as an optimal tool for the development of a novel therapeutic approach for thyroid
cancer.
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Thyroid carcinoma accounts for roughly 1% of all new malignant
tumours, and a majority of thyroid cancers are well differentiated,
including papillary, follicular and Hu ¨rthle cell carcinoma. In most
patients, the management of well-differentiated thyroid cancer is
partial or complete thyroidectomy in conjunction with chemo- or
radioiodine therapy. However, a substantial number of patients
with differentiated thyroid cancer do not respond to radioiodine
therapy, and 5–20% of them develop lung metastases, which, in
most cases, do not respond to radioiodine therapy and are
inoperable. Therefore, new complementary therapeutic approaches
could be of interest in the treatment of thyroid carcinomas.
Thyroperoxidase (TPO) is expressed on the apical membrane of
both normal and malignant thyroid cells. Indeed, unlike other
thyroid-specific antigens, such as thyroglobulin and TSH receptor
that are no longer expressed in thyroid carcinomas, TPO
expression persists even on poorly differentiated thyroid tumours
(Czarnocka et al, 1985). Therefore, TPO expressed at the surface of
thyroid cancer cells can be recognised by anti-TPO autoantibodies
(aAbs) and might constitute a potential target for antibody-specific
immunotherapy. Thyroperoxidase is one of the major autoantigens
involved in autoimmune thyroid diseases (AITD), such as
Hashimoto’s thyroiditis (McLachlan and Rapoport, 1992, 2000).
Hashimoto’s thyroiditis is characterised by glandular hypo-
function, destruction of thyroid cells and production of an
immunoglobulin G (IgG) response directed against TPO. Anti-
TPO aAbs are invaluable markers of thyroid autoimmune response
and have been shown to exert both in vitro and in vivo cytotoxic
functions such as C3 complement activation (Wadeleux et al,
1989; Chiovato et al, 1993; Parkes et al, 1994) and anti-
body-dependent cell-mediated cytotoxicity (ADCC) (Bogner et al,
1989; Rodien et al, 1996; Guo et al, 1997; Metcalfe et al, 1997;
Rebuffat et al, 2008). These effects probably participate in the
maintenance and amplification of thyroid cell destruction in
Hashimoto’s disease. On the basis of these observations, one could
envision the use of anti-TPO aAbs as potential antigen-specific
agents with cytotoxic activities for the treatment of thyroid
carcinomas.
In addition, it is well known that in AITD such as Hashimoto’s
disease, lymphocytes infiltrate and destroy thyroid gland. Previous
reports have suggested that the immune system attempts to control
cancer thyroid cells. Indeed, lymphocytes as well as monocytes/
macrophages are often found in the periphery or infiltrated in the
tumours, which make them potential effectors involved in the
destruction of cancer cells.
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characterised human recombinant anti-TPO aAbs (Chapal et al,
2000, 2001). These human recombinant anti-TPO aAbs mimic
human anti-TPO aAbs present in the sera of patients suffering
from AITD and recognise the human TPO (hTPO) immunodomi-
nant region (Bresson et al, 2003, 2004, 2005, Rebuffat et al, 2006).
To evaluate if these anti-TPO aAbs may be useful tools in the
treatment of thyroid carcinomas, we selected a human recombi-
nant anti-TPO aAb and expressed it in baculovirus (B4) and in
CHO cells (B40). We explored their biological properties in vitro
before future in vivo preclinical tests. Cytotoxic activity, comple-
ment-dependent cytotoxicity (CDC) and ADCC, of purified human
recombinant anti-TPO aAbs (B4 and B40) expressed in respectively
baculovirus and CHO cells, were studied on thyroid carcinoma
cells and compared with those of circulating anti-TPO aAbs
purified from the sera of patients suffering from AITD, using the
same target cells. We show here that anti-TPO aAb B40 purified
from CHO is able to induce a moderate cytotoxic activity, lower
than that of patients’ circulating anti-TPO aAbs on the papillary
carcinoma cell line NPA, whatever the effector cells used
(peripheral blood mononuclear cells (PBMC) or monocyte cell
line). However, neither human recombinant anti-TPO aAbs B4
purified from baculovirus/insect cells nor deglycosylated aAbs
from patients’ sera appear able to induce any significant CDC,
ADCC or anti-proliferative activity.
MATERIALS AND METHODS
Reagents
Human recombinant anti-TPO scFv antibody B4 was selected in
our laboratory using a phage-display library and expressed as IgG1
in baculovirus/insect cells system by Dr M Cerutti as previously
described (Bresson et al, 2001, 2003). Sera from patients suffering
from Graves’ disease were obtained from Dr B Guerrier (Guy de
Chauliac Hospital, Montpellier, France) and Dr L Baldet (Lapeyronie
University Hospital, Montpellier, France). IgG1 antibodies were
purified on a protein G affinity column and the concentration
determined by absorbance at 280nm, E
0.1% of 1.40. Human sera
anti-TPO aAbs were deglycosylated using the Dig Glycan
differentiation kit (Roche, Basel, Switzerland). Mouse monoclonal
anti-hTPO antibodies mAb15 and mAb47 were provided by Dr J
Ruf (INSERM Unit 555, Marseille, France). Human TPO, purified
(more than 95% pure) from thyroid glands, was obtained from
HyTest Ltd (Turku, Finland).
Cells
Human anaplastic thyroid cancer cell lines SW1736 and C643
(Mark et al, 1987) were kindly provided by Dr NE Heldin,
Denmark, and human follicular thyroid cancer cell lines ML1
(Schonberger et al, 2000) and WRO (Estour et al, 1989) were from
J Schonberger. The human papillary thyroid cancer cell line NPA
was a gift from Professor Santoro, Italy (Fagin et al, 1993). Cells
were cultured in RMPI 1640 (Cambrex, Belgium) containing 10 %
fetal calf serum (FCS) (PAA Laboratories, Linz, Austria), 2mM
L-glutamine, 100Uml
 1 of penicillin and 100mgml
 1 of strepto-
mycin (Life Technologies Inc., Paisley, UK).
Peripheral blood mononuclear cells obtained from healthy
donors (Etablissement Franc¸ais du Sang, Montpellier, France)
were separated from blood by Ficoll density gradient (Histopaque-
1077; Sigma-Aldrich, St Louis, MO, USA) and resuspended in
RPMI 1640 supplemented with 10% heat-inactivated FCS,
50Uml
 1 penicillin, 50mgml
 1 streptomycin and 2mmoll
 1
glutamine.
The 11A1.6 CD64
þ (van Vugt et al, 1999), CDw32-L CD32
þ
(Peltz et al, 1988) and Jurkat CD16
þ (Vivier et al, 1992) cell lines
were kindly provided by Professor J van de Winkel, Dr J Lewsen
(Immunotherapy Laboratory, Utrech University, The Netherlands),
Dr JP Vendrell (Virology Laboratory, University Hospital,
Montpellier, France) and Professor E Vivier (INSERM U608,
Marseille, France) respectively.
The effector cell line (HL-60), a human monocyte line (provided
by J Dornand, Montpellier), was grown in the same medium as
PBMC. Five days before the experiment, 1,25-dihydroxyvitamin D3
(1,25(OH)2D3)(¼D3 vitamin) was added to induce differentiation
of HL-60 cells into monocytes. All cell cultures were incubated at
371C in a humidified atmosphere containing 5% CO2. Metho-
trexate (5mM; Sigma-Aldrich) and geneticin (G418) (0.5mgml
 1;
Sigma-Aldrich) were added, respectively, to 11A.6 CD64
þ and
Jurkat CD16
þ cell lines.
The expression of CD14, CD16 (FcgRIII), CD32 (FcgRII), CD64
(FcgRI) on the surface of the different effector cells (HL-60 and
PBMC) was investigated using fluorescein-conjugated anti-human
CD Ab (Miltenyi Biotech, Bergisch Gladbach, Germany and
Pharmingen, Becton Dickinson, Franklin Lakes, NJ, USA) and
analysed by flow cytometry analysis as previously described
(Rebuffat et al, 2008). Monocytes and lymphocytes present in
PBMC were identified by size/structure analysis.
Expression and production of recombinant human
anti-TPO antibody in CHO cells
The recombinant human anti-TPO scFv B4 was selected from an
antibody phage-display library obtained from B cells extracted
from thyroid tissue of patients suffering from Graves’ disease
(Chapal et al, 2001). ScFv B4 was expressed as a whole IgG1
antibody in the baculovirus/insect cell system (anti-TPO recombi-
nant aAb B4). To improve glycosylation of the Fc part of this
recombinant antibody, we also expressed scFv B4 as an IgG1 in the
CHO eukaryote system (anti-TPO recombinant aAb B40). The
variable heavy chain of B4 was cloned between BamHI and NheI
restriction sites in the plasmid vector pcDNA3 (Invitrogen Life
Technologies, Carlsbad, CA, USA) containing the sequence of the
heavy chain (pcDNA3/H) and the variable light chain of B4
between BamHI and XhoI in another plasmid vector pcDNA3
containing the sequence of the light chain (pcDNA3/L). These two
plasmid vectors were kindly provided by Stephane Birkle (Alvarez-
Rueda et al, 2007). Expression plasmids pcDNA3/L and pcDNA3/H
were transfected into CHO cells using a Polyfect Transfection
Reagent kit (Qiagen GmbH, Germany) according to the manu-
facturer’s instructions. Cells were selected in the presence of
0.5mgml
 1 G418 and 0.5mgml
 1 Zeocin (Invitrogen Life
Technologies). Double-resistant clones were isolated by limiting
dilution, and the supernatants of resistant transfectants screened
by ELISA. The anti-TPO recombinant aAb B40 IgG1 was purified on
a protein G affinity column and the concentration determined by
measuring the absorbance at 280nm, E
0.1% of 1.40.
Flow cytometry analysis of TPO expression on the
membrane of human thyroid cancer cell lines
Cells were removed from the culture flasks using HEPES–EDTA
buffer (HEPES 10mM, EDTA 3mgml
 1, pH 7.0), rinsed and
pelleted (5min, 1000r.p.m., 41C) in Dulbecco’s phosphate-buffered
saline (D-PBS) (Cambrex) containing 2% FCS (¼F-buffer).
Approximately 10
6 cells were incubated with 200ml of F-buffer
containing 10mgml
 1 of human anti-TPO aAb for 60min at 41C,
then washed twice and further incubated in 200ml of F-buffer
containing 10mgml
 1 of fluorescein-conjugated anti-human IgG
g-chain-specific Ab (Sigma-Aldrich) for 60min at 41C in the dark.
Negative controls were performed by incubating cells with only the
secondary antibody. After two washings with D-PBS, the cells were
analysed (10000 events) with an EPICS XL4 (Beckman-Coulter,
Fullerton, CA, USA) fluocytometer.
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bound to TPO expressed on the membrane of NPA cells
Flow cytometry analysis was carried out as previously described.
NPA cells (B10
6) were incubated with human anti-TPO aAb (B4,
B40 or purified from sera of patients suffering from AITD); the
reaction was revealed with a secondary antibody and analysed with
an EPICS XL4 fluocytometer.
Flow cytometric analysis of human anti-TPO antibodies
bound to the FccR
Cells expressing specifically one FcgR and effector cells (PBMC
and HL-60) were rinsed and pelleted (5min, 1000r.p.m., 41C) in
F-buffer. The cells (B10
6) were incubated for 90min at 41C
with 200ml of F-buffer containing 10mgml
 1 of the complex
TPO/human anti-TPO aAb (B4, B40 and aAbs purified from sera
of patients suffering from AITD, preliminary incubated with
hTPO (HyTest Ltd) for 45min at 41C). They were then washed,
incubated with 10mgml
 1 of fluorescein-conjugated anti-human
IgG g-chain-specific antibody and binding analysed as previously
described.
In vitro antibody-dependent cell-mediated cytotoxicity
assay
Antibody-dependent cell-mediated cytotoxicity assays were carried
out using the standard
51Cr release assay (Rebuffat et al, 2008).
Target cells (NPA cell line) were removed from culture flasks using
HEPES–EDTA buffer, rinsed and aliquots (B10
6 cells) incubated
(371C, 60min, 5% CO2) in culture medium 100mCi
51Cr. Cells were
then washed to eliminate unincorporated
51Cr and labelled target
cells incubated (41C, 45min) with human anti-TPO antibodies (B4
and B40 or aAbs purified from sera of patients suffering from
AITD) (50mgml
 1). They were then seeded (2 10
4 cells per well)
in 96-well U-bottomed culture plates and incubated with effector
cells (effector/target ratio, 50:1 PBMC, 12:1 HL-60). As controls,
Jurkat cells were submitted to the same conditions than NPA cells
and an irrelevant human IgG from healthy subjects or culture
medium alone were used. Target cells were used to determine
spontaneous
51Cr released in culture medium only and total
51Cr
release was assessed by addition of HCl (1 N). Tests and controls
were performed in triplicate. Cells were incubated for 6h (371C,
5% CO2), centrifuged (5min, 1000g) and aliquots (100ml) sampled
for g-counting. Cytotoxicity was expressed as specific
51Cr release
calculated as follows: Lysis¼((c.p.m. with effector cells) – (c.p.m.
with culture medium))/((c.p.m. with HCl) – (c.p.m. with culture
medium)).
Complement fixation assay
To study the ability of TPO/anti-TPO antibody complexes to bind
to C1q complement, microtitre plates were coated with TPO/anti-
TPO aAbs (B4 and B40 and aAbs purified from patients’ sera)
complexes, in 100mM NaHCO3 (pH 9.0) at 41C overnight. The
plates were washed three times with D-PBS-Tween 0.1% and
blocked with 1% non-fat powdered milk in D-PBS-Tween 0.1%
(blocking buffer) for 60min at 371C. After washing, C1q
complement was incubated in the blocking buffer for 90min at
371C. Plates were then washed and anti-C1q antibody was added
for 60min at 371C. After washing, peroxidase-conjugated anti-
mouse IgG (diluted 1:1000 in the blocking buffer) was incubated
for 60min at 371C. After three washings, binding of C1q to anti-
TPO aAb was detected by addition of 4mgml
 1 2-phenylenedia-
mine solution containing 0.03% (v/v) hydrogen peroxide in 0.1 M
citrate buffer (pH 5.0). The reaction was stopped with 2 M H2SO4
and the resulting absorbance measured at 490nm.
In vitro complement-dependent cytotoxicity assay
To test complement-mediated cytotoxicity, NPA cells (10
6) were
labelled with 100mCi
51Cr for 60min at 371C. After washing,
labelled target cells were distributed (2 10
4 cells per well)
in 96-well U-bottomed culture plates. Target cells (triplicate wells)
were incubated (41C, 45min) in culture medium in the absence or
presence of an anti-TPO aAb (50mgml
 1) (recombinant B4, B40,
aAbs purified from sera of patients suffering from AITD or
monoclonal antibodies (mAb15 and mAb59) known to target
two different regions on TPO surface (Ruf et al, 1989)). Cells
were incubated for 4h at 371C, with a source of Complement
(guinea pig serum; Sigma-Aldrich). After centrifugation (5min,
1000g), aliquots (100ml) of the supernatant were sampled for
g-counting. Cytotoxicity was expressed and calculated as pre-
viously described.
Papillary thyroid cancer cell proliferation assay
NPA cell growth was assessed after 5 days of culture using the cell
bromodeoxyuridine (BrdU) proliferation kit (Roche) according
to the manufacturer’s instructions. NPA cells were cultured in
triplicate in 96-well culture microplates at 2 10
4 cells per well
(Techno plastic products, Trasadingen, Switzerland) in 200mlo f
culture medium in the absence or presence of 50mgml
 1 of anti-
TPO recombinant aAbs (B4 or B40) or anti-TPO aAbs from
patients’ sera used as inhibitors. Microplates were then incubated
for 4 days at 371C in a wet atmosphere containing 5% CO2.
Bromodeoxyuridine 1:100 dilution was then added, and micro-
plates incubated for an additional 24h. Bromodeoxyuridine
incorporation was measured using a horseradish peroxidase-
conjugated anti-BrdU antibody and o-phenylenediamine (100ml
per well) as substrate. The colorimetric reaction was stopped by
addition of 50mlo f4 N sulphuric acid per well and absorbance
measured at 490nm.
RESULTS
Thyroid cancer and effector cell lines characterisation
Before testing the potential use of anti-TPO aAbs for immuno-
therapy of thyroid cancer by cytotoxic assays (ADCC and CDC),
we first characterised the target and effector cells. Expression of
thyroperoxidase was investigated in five potential target cells,
human anaplastic (SW1736 and C643), follicular (ML1 and WRO)
and papillary (NPA) thyroid cancer cell lines. Thyroperoxidase
was found to be expressed in 100% of papillary thyroid cells line
(NPA) vs in only 43 and 69% of, respectively, ML1 and WRO
follicular thyroid cancer cells. As expected human anaplastic
cancer cells (SW1736 and C643) poorly expressed TPO on their
cell surface (Figure 1A). Various populations of effector cells
exert different functions by FcR-mediated antibody-antigen
binding. FcgRI (CD64) (the high-affinity IgG receptor), FcgRIIa
(CD32) and FcgRIII (CD16) (the low-affinity IgG receptor) are
activating receptors present on a wide range of myeloid cells
(monocytes, macrophages, dendritic cells, neutrophils and natural
killer (NK) cells). As we previously showed (Rebuffat et al, 2008)
that monocytes are potential effector cells in AITD, the monocyte
cell line HL-60 and PBMC were chosen as effector cells for
cytotoxic assays. We characterised these cells regarding monocytes
surface markers such as CD14 and FcgR expression. The
differentiation of HL-60 into monocytes with D3 vitamin was
assessed by determining CD14 expression (98.26%). Flow cyto-
metry analysis showed that FcgRII (CD32) and FcgRI (CD64)
are expressed on the HL-60 cell line and on the monocyte
population present in PBMC (more than 90% of cells were
stained). On the other hand, FcgRIII (CD16) was only present on
Cytotoxic activity of human recombinant anti-TPO aAbs
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cells (Figure 1B).
Human recombinant anti-TPO aAbs B4, B40 and patients’
sera exhibit different binding properties to FccRs and
ADCC activity
Before studying the ability of human recombinant anti-TPO aAbs
B4 and B40 and affinity purified IgG from patients’ sera to mediate
ADCC, we evaluated their binding capacity. Therefore, we
measured binding of aAbs to TPO expressed on NPA cells
(Figure 2A), and binding of TPO/anti-TPO complexes on FcgRI
(CD64), FcgRII (CD32) and FcgRIII (CD16) expressed by both CD
cell lines (Figure 2B) and effector cells (Figure 3A and B). As
indicated in Figure 2A, similar cytometry patterns, showing the
binding of anti-TPO aAbs on NPA target cells, occurred with
human recombinant anti-TPO aAbs B4 and B40 (91.96 and 98.77%,
respectively). This shows that the expression system used for the
anti-TPO aAb (baculovirus/insect cell or in CHO cell) does not
modify specificity of the aAb. Furthermore, anti-TPO aAbs
purified from patients’ sera, which are polyclonal and recognise
different epitopes on the TPO molecule, exhibit a comparable
binding profile (99.97% of stained cells). The reactivity of
complexes of the human recombinant anti-TPO aAbs and patients’
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Figure 1 Thyroid cancer and effector cell lines characterisation. (A) TPO expression was investigated by flow cytometry on papillary (NPA), follicular
(ML1 and WRO) and anaplastic thyroid cancer (SW1736 and C643) cell lines. Cells were incubated successively with a human anti-TPO antibody and with
an anti-human FITC antibody. Data correspond to the average of two experiments. (B) Expression of four specific markers (CD14, CD16, CD32 and
CD64) was studied on effector cells: peripheral blood mononuclear cells (entire PBMC, lymphocytes and monocytes) and a monocyte cell line (HL-60).
CD14 is only expressed on monocytes; Fcg receptors CD16 on lymphocytes, CD32 and CD64 on monocytes. Conjugated controls show no background
staining.
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ssera with TPO was analysed using cell lines 11A1.6 CD64
þ,
CDw32-L CD32
þ and Jurkat CD16
þ, which express only one type
of FcgR (CD16, CD32 or CD64). Only anti-TPO aAbs from patients’
sera were able to bind the three types of FcgRs with a staining value
of 30.99, 54.21 and 81.69% for CD64, CD32 and CD16, respectively.
The two human recombinant anti-TPO aAbs (B4 and B40)
exhibited no major differences in binding profile for CD32 and
CD16. However, B40 exhibited a stronger binding affinity than B4
(83.19 vs 22.66%) for CD64 (Figure 2B). An anti-FcgRs Ab, used as
control, abolished the binding of the immune complex to the
effector cells and confirmed that binding of human anti-TPO aAbs
involves their Fc region (data not shown). Finally, if Ab
deglycosylation only moderately alters antigen binding, it sig-
nificantly modifies the binding of FcgR on human cell lines
(Figure 2B). Taken together, these data suggest that the TPO-anti-
TPO aAbs were able to bind FcgR of cell lines expressing CD16,
CD32 and CD64 (Figure 2B).
The next step was to examine the binding of these complexes on
effector cells, lymphocyte and monocyte populations present in
PBMC as well as HL-60 cells used in ADCC assays. The anti-TPO
aAbs (patients’ sera, B4 and B40) bound HL-60 cells by their Fc
domain (Figure 3A). However, binding of the aAbs on PBMC
showed different patterns due to the level of FcgRs expression on
these cell populations. The anti-TPO aAbs purified from patients’
sera and B4 expressed in baculovirus/insect cell system, which
appeared able to bind the three FcgR types (Figure 3B), strongly
interacted with the monocyte and lymphocyte populations present
in PBMC. In contrast, the human recombinant anti-TPO aAbs
expressed in CHO cells (B40) bound 90% of the monocyte
population but only 40% of the lymphocyte population (most
probably NK cell lymphocytes). Thereafter, the ability of
recombinant and circulating anti-TPO aAbs to lyse papillary
thyroid cancer cells was explored using systems detecting ADCC
with the monocyte cell line HL-60 and PBMC as effector cells and
NPA cells as targets, because 100% of these cells express TPO on
their cell surface. The capacity of recombinant anti-TPO aAbs (B4
and B40) and purified aAbs from patients’ sera to exhibit ADCC
was tested (Figure 3C). Anti-TPO aAbs purified from patients’ sera
lysed 24–29% of NPA cells, whereas the human recombinant anti-
TPO aAbs were less effective (B4 (3.5–10%) and B40 (9–19.5%)). It
is worth noting that Jurkat cells, used as a control, were insensitive
to anti-TPO aAbs, showing the specificity of these antibodies to
lyse NPA cells. Interestingly, whatever the aAbs used (patients’
sera, B4 or B40), a greater ADCC efficiency was obtained with
PBMC than with the monocyte cell (29% for PBMC vs 24% for HL-
60). This result is in accordance with the expression by PBMC of
three types of FcgRs (CD16 on lymphocytes NK cells, CD32 and
CD64 on monocytes) whereas monocyte cells HL-60 express only
FcgRI (CD64) and FcgRII (CD32). From the comparison of the
ADCC activity of the different anti-TPO aAbs, it appears that the
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Figure 3 Antibodies-dependent cellular cytotoxicity (ADCC) mediated by human recombinant anti-TPO aAbs (B4 and B40) and patient’s sera anti-TPO
aAbs. (A and B) Binding of TPO/anti-TPO complexes on effector cells (HL-60 cell line and PBMC) was analysed by flow cytometry. (C) Antibodies-
dependent cellular cytotoxicity was determined by the
51Cr release assay. Human thyroid cells were incubated with irrelevant Abs (&) or human anti-TPO
aAbs purified from sera of patients suffering from AITD ( ), B4 ( ) and B40 ( ) with different effector cells (PBMC and HL-60). Y axis presents the
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than the recombinant aAbs expressed in CHO system (B40) and
finally the anti-TPO aAbs expressed in baculovirus/insect cell
system (B4). This shows once again that the carbohydrate residues
are crucial for the cytotoxic activity of the Abs.
Human recombinants anti-TPO aAbs B4, B40 and patients’
sera mediate CDC on NPA cells
Activation of the Complement membrane attack complex (MAC;
C5b-9) can lead to direct lysis of target cells by complement-
dependent cytotoxicity (CDC). This can occur by the classical
pathway with the C1 component, after binding of antibodies to the
target cells. To determine whether human recombinants and
patients’ sera anti-TPO aAbs act through a CDC mechanism on
NPA cells, we investigated if C1q component binds to the immune
complex anti-TPO aAbs/TPO. As expected, our ELISA data show
that C1q does bind to the different complexes (Figure 4A). In
contrast, an irrelevant IgG used as control failed to bind the C1q.
As tumour cells often evade complement activation because they
express membrane-bound complement regulatory proteins, we
investigated the relative surface expression of three of the main
complement regulatory proteins: CD46 (membrane cofactor
protein), CD55 (decay-accelerating factor) and CD59 (protecting)
by flow cytometry on NPA cells (Figure 4B). NPA cells expressed
all the three proteins, with a greater expression of CD59 and CD55
than CD46 proteins, suggesting that NPA tumour cells were
obviously protected against CDC. The ability of Complement to
destroy papillary tumour cells was investigated. About 34% of cell
lysis (Figure 4C1) was observed when
51Cr-labelled NPA cells
were incubated with human anti-TPO aAbs purified from patients’
sera and guinea pig serum. A lower CDC was observed with
recombinant anti-TPO aAbs B40 (9% of cell lysis), whereas no
complement cytotoxic activity was detected using recombinant
anti-TPO aAbs B4. Finally, with regard to the CDC activity
for the three human (recombinants and patients’ sera) anti-TPO
aAbs, we used two mAbs (mAb15 and mAb59) directed against
two distinct epitopes on the TPO molecule to determine if the
epitope recognition by anti-TPO Abs affects CDC mechanism.
Figure 4C2 shows a weak and similar CDC with both mAb15
and mAb59 (7 and 9% cell lysis, respectively) showing that, in our
case, the epitopic recognition has no function in anti-TPO Abs
CDC activity; thus differences observed between anti-TPO aAbs
(B4, B40 and patients’ sera) could be due to the polyclonality
of the latter.
Anti-TPO aAbs partially inhibit NPA cells proliferation
The growth of NPA cells cultured in the presence of the anti-TPO
recombinant aAbs (B4 and B40) and anti-TPO aAbs from sera of
patients suffering from AITD was partially inhibited (18, 16 and
25%, respectively) but not in control cells cultured in medium
alone (Figure 5).
DISCUSSION
We previously showed that TPO aAbs are, through both ADCC and
CDC, able to damage human thyroid cells on binding to TPO
expressed on the cell surface (Rebuffat et al, 2008). In this study,
we hypothesised that human recombinant anti-TPO aAbs could
be used to destroy thyroid tumour cells and thus to develop a
complementary therapeutic approach in thyroid cancers. Before
testing anti-TPO Abs in in vivo trials, we compared the in vitro
cytotoxic activities of baculovirus-expressed, CHO-expressed
human IgG1 anti-TPO aAbs named B4 and B40 with those of
purified anti-TPO IgG of patients’ sera, on papillary thyroid cancer
cells expressing TPO. In this study, we show that anti-TPO aAbs,
purified from patients’ sera and CHO-expressing human recombi-
nant B40 aAbs are able to induce moderate CDC, ADCC as well as
anti-proliferative effects on NPA cells. In contrast baculovirus-
expressing human recombinant B4 displayed no or only minor
cytotoxic activities.
We focused this study, until now the only one, on the possible
use of anti-TPO aAbs in thyroid cancer immunotherapy to
improve the efficiency of conventional treatments and especially
in carcinoma that do not respond to radioiodine therapy. In this
respect the human anti-TPO aAbs (patients’ sera and B40 aAbs
expressed in CHO) tested here exhibit some cytotoxic properties.
Their specificity for TPO in targeting thyroid cancerous cell, their
capacity to bind the C1q complement and their simultaneous
recruitment of immune effector cells by binding to FcgR through
their Fc region agree with the concept that they could be
considered as potential tools for passive immunotherapy.
If purified anti-TPO aAbs present in patients’ sera, and to a
lesser extend B40 (anti-TPO aAbs expressed in CHO), mediate
cytotoxic activity against thyroid cells, only partial or no
effects were triggered by B4 (anti-TPO aAbs expressed in
baculovirus). The low ADCC activities are probably due to the
low glycosylation level of aAbs expressed in baculovirus. Indeed,
the presence of specific oligosaccharide structures linked to the
Cg2 domain of the Fc fragment has been reported to affect the
biological activity of the antibody (Jefferis et al, 1998; Lifely et al,
1995; Wright and Morrison, 1997) by influencing the interaction
with FcgRs (Tao and Morrison, 1989). In this context, biophysical
and molecular studies have shown that N-acetylglucosamine
(GlcNac) in the triantennary N-glycan seems also required to
induce ADCC. The baculovirus-expressing system used does not
incorporate GlcNac in proteins, which probably accounts for the
lower cytotoxic activity mediated by the baculovirus-expressed
anti-TPO aAb B4.
The biological responses triggered on FcgRs stimulation depend
on the nature of cells expressing the receptor rather than on the
receptor itself. Antibody-dependent cell-mediated cytotoxicity
functions have been shown to be shared by various cell
populations, including monocytes, NK cells and granulocytes
(Ortaldo et al, 1987; Steplewski, 1993). Here, we used PBMC.
A significant and more efficient ADCC has been obtained using
human anti-TPO aAbs from patients’ sera and PBMC. This result is
probably due to (1) the use of correctly glycosylated Abs (as
discussed above) and (2) the expression of all three types of FcgRs:
FcgRI (CD64), FcgRII (CD32) and FcgRIII (CD16) on the different
cell populations in PBMC. Indeed, HL-60 cells express only FcgRI
and FcgRII, whereas PBMC include lymphocytes NK cells (bearing
the FcgRIII), monocytes and granulocytes (bearing FcgRI and
FcgRII). These data show that anti-TPO aAbs are able to mediate
higher ADCC with PBMC as effector cells.
Complement-dependent cytotoxicity activity depends on the
binding of C1q on immune complexes and can be modulated by
the presence on tumour cell of membrane-bound complement-
regulated proteins. All the anti-TPO aAbs we used bind to C1q
but differences are observed in their CDC activity; a maximal
efficiency is obtained using anti-TPO aAbs purified from patients’
sera. One possible explanation is the polyclonality of the anti-TPO
aAbs purified from patients’ sera resulting in (1) recognition
of a larger number of epitopes of TPO on target cells and (2)
deposition of an increased number of complement fragments on
these tumour cells, after activation of the complement system.
Furthermore, in classical complement activation pathway,
CD55 (Bjorge et al, 1997) and CD59 (Brasoveanu et al, 1996;
Gorter et al, 1996) have the most prominent function in regulating
the MAC, thus preventing cell lysis. These regulatory proteins are
expressed on NPA cell membrane and probably partially protect
them from CDC. Combining the various human recombinants
anti-TPO aAbs we selected by phage display and characterised in
term of epitopes (Bresson et al, 2003, 2004; Chapal et al, 2000;
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complement activation.
Finally, the use of a mix of anti-TPO aAbs resulting in the
simultaneous presence of multiple non-competing TPO epitopes
should also improve detection of TPO on cancer cell surface, an
essential feature for thyroid cancer treatment. It is now well
established that the density of target antigen expressed at the cell
surface is essential to obtain a pronounced cytotoxic activity. If
compared with the HER-2 antigen in breast cancer, TPO is less
expressed in NPA cells, explaining the low levels of complement-,
cell-mediated cytotoxicity and anti-proliferative effects we
observed. However, studies concerning TPO expression in thyroid
cancer yielded discrepant data; some studies reported an inverse
correlation between TPO and proliferative cell membrane antigen
(Garcia et al, 1998), whereas others pointed to a normal TPO
expression in the majority of thyroid carcinomas (more than 65%)
(Czarnocka et al, 2001). Using flow cell sorting technique, we
analysed TPO expression on papillary (NPA), follicular (ML1 and
WRO) and anaplastic (SW1736 and C643) human thyroid cancer
cell lines, and showed that TPO is present on all the cell lines tested
even though it was found less expressed in anaplastic and follicular
thyroid cancer when compared to papillary carcinoma. These
results agree with the study of Czarnocka et al (2001) showing that
TPO is still expressed on thyroid cancer cells but not with the
study of Garcia et al (1998). These conflicting data could result
from differences in the methods and anti-TPO Abs used to detect
TPO. Indeed, Garcia et al (1998) investigated TPO expression in a
series of thyroid tumours by immunostaining using the anti-TPO
mAb47 (Ruf et al, 1989). We have previously shown that lysine 713
has a critical function for TPO epitope recognition by mAb47
Concentration
(g ml–1)
O
D
 
(
4
9
0
 
n
m
)
Control
Anti-TPO Ab from patient with AITD
Anti-TPO recombinant Ab (B4)
Anti-TPO recombinant Ab (B4′)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Anti-TPO recombinant Ab (murin mAb)
L
y
s
i
s
 
(
%
)
0
4
8
12
mAbs murins
mAb15 mAb59 SC o n t r o l
0
10
20
30
40
L
y
s
i
s
 
(
%
)
S Anti-TPO
recombinant
Ab (B4)
Anti-TPO Ab
from patient
with AITD
Anti-TPO
recombinant
Ab (B4’)
Control
E
v
e
n
t
s
101 102 103 10
0
136
273
409 Control
CD46
CD55
Fluorescent intensity
CD59
0.01 0.1 1 10 100
Figure 4 Complement-dependent cytotoxicity mediated by human recombinants (B4 and B40) and patients’ sera anti-TPO aAbs. (A) The C1q
component of Complement was able to bind to TPO/anti-TPO aAbs complexes but not to an irrelevant IgG. Binding was determined by ELISA. Results are
mean of duplicates. (B) Expression of complement regulatory proteins CD46, CD55 and CD59 was investigated on NPA cells, by flow cytometry and the
data presented in histograms were overlaid. (C) Complement-dependant cytotoxicity was determined by the
51Cr release assay. Y axis presents the
percentage of NPA cells lysis. NPA cells were lysed by the complement in presence of human (C1) or murin anti-TPO aAbs (C2). Bars, s.d. Results are
means of duplicates.
Cytotoxic activity of human recombinant anti-TPO aAbs
SA Rebuffat et al
859
British Journal of Cancer (2010) 102(5), 852–861 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s(Bresson et al, 2004), which is probably strongly impaired by
cross-linking of the amino acid on formaldehyde slide fixation.
Czarnocka et al (2001) used a TPO capture method that has the
advantage to preserve integrity of the antigen structure and
thereby allows immunological detection.
Currently, numerous efforts are being made to develop
immunological tools for immunotherapy. The presence of TPO
in various thyroid carcinoma and metastases, but not in the other
tissues, makes it tempting to target thyroid cancer cells with
specific anti-TPO Abs.
Our in vitro data show that anti-TPO aAbs do exhibit some
capacities to destroy NPA thyroid tumour cells by ADCC or CDC
but in the present state, cannot be considered as suitable for
thyroid cancer immunotherapy. Progress has to be made in
improving anti-tumour capacities of these anti-TPO recombinant
aAbs. This is the matter of our present investigations, with the
engineering of CD16/anti-TPO bi-specific aAbs able to physically
cross-link immune and tumour cells and thereby to improve
cytotoxic activity.
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